Abstract
The pathology of Alzheimer’s disease (AD) is characterized by the extracellular and intracellular accumulation of amyloid-β (Aβ) fibrillar plaques formed by the Aβ1-42 peptide, neurofibrillary tangles (NFTs) consisting of hyperphosphorylated tau, extensive neuritic and synaptic degradation, and neuron loss. One of the priorities for the treatment of AD is both the early detection and accurate chart progression of the accumulation of Aβ plaques in human brains. Molecular imaging tools can provide an in vivo visualization of Aβ plaques. Specific identification of amyloid plaques would allow a more accurate prognosis and ensure more effective clinical trials of anti-amyloid agents at earlier disease stage. The emphasis of this review is on the development of Aβ peptide radiopharmaceuticals or the ones combined with nanocarrierbased such as Molecular Trojan horses or nanoparticles for applications in in vivo amyloid imaging in AD.
Keywords: Alzheimer’s diagnosis, amyloid plaque imaging, amyloid radiopharmaceuticals, blood-brain barrier.
Related Books
Frontiers in Clinical Drug Research - Anti-Cancer Agents
The Management of Metastatic Triple-Negative Breast Cancer: An Integrated and Expeditionary Approach
Cancer Genes
Cancer Medicine in an Ayurvedic Perspective: A Critical Overview
Cancer Genes
Anticancer Immunity: Reviewing the Potential of Probiotics
Probiotics in Anticancer Immunity
Phytonutrients in the Treatment of Gastrointestinal Cancer
Molecular Targets and Cancer Therapeutics (Part 2)
Molecular Targets and Cancer Therapeutics (Part 1)
56